Peptides are short chains of amino acids linked together by peptide bonds. Peptides are molecules that are commonly referred to as proteins, and the functions of which are determined by the amino acid sequence and size.
Heparin is a disaccharide anticoagulant, also known as a blood thinner, that prevents blood clots from forming. Heparin is produced by mast cells and basophils in the body, and it is stored in mast cells and secreted wherever injuries occur.
The global peptide and heparin market is expected to grow at a high single-digit CAGR over the forecast period, according to Fact.MR (2021-2031). By the end of 2026, the peptide and heparin market is expected to generate nearly US$ 35,000 million in revenue.
- Region North America
- Latin America
- Product Type Sodium Heparin
- Ammonium Heparin
- lithium Heparin
- Other Product Types
- Route of Administration Intravenous
- Oral Route
- Indication Diabetes
- Metabolic Disorder
- Central Nervous Systems
- Other Indications
- Distribution Channel Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Because of the large number of international and regional vendors, the global market for peptides and heparin is highly fragmented and competitive.
These companies are constantly working on generic formulations for blood coagulation and a variety of other novel therapeutic areas.
Companies that can produce drugs that are effective at treating coagulation disorders and have high efficacy and safety profiles are likely to gain the most market share shortly.
Key market participants identified by the report include
- Bio for S.p.A,
- Hemmo Pharma
- AmbioPharm Inc.
- Wockhardt Ltd.
- Sun Pharmaceutical Industries Ltd.
- Abbott Laboratories
- Pfizer Inc
- Leo Pharma
- Novo Nordisk
- Eli Lilly.
Get a Sample Copy of this Report (Including Full TOC, Table & Figures)